Merck & Co., Inc. (MRK)

76.43
0.21 0.28
NYSE
Prev Close 76.22
Open 75.97
Day Low/High 75.87 / 76.76
52 Wk Low/High 65.25 / 89.20
Volume 8.22M
Exchange NYSE
Shares Outstanding 2530.32B
Market Cap 193.09B
P/E Ratio 17.80
Div & Yield N.A. (N.A)

Latest News

Jim Cramer: The Rush to Reopen Is Ill-Advised

Jim Cramer: The Rush to Reopen Is Ill-Advised

Only 7% of Texas is vaccinated, or two million people. I don't want to mess with Texas or Texans until that number is higher.

Biotech Isn't Seeing Much Merger Activity, but Here's a Stock to Like

Biotech Isn't Seeing Much Merger Activity, but Here's a Stock to Like

Dynavax Technologies has inked a supply deal related to a Covid-19 vaccine that could greatly increase its revenue stream.

Jim Cramer: What History Tells Us About Bond-Rate Scares Like This

Jim Cramer: What History Tells Us About Bond-Rate Scares Like This

We could have some real pain ahead for some stocks. Five different kinds.

Night-Time Running and Trading, Tech Beatdown, Yellen on Bitcoin, My Nvidia Plan

Night-Time Running and Trading, Tech Beatdown, Yellen on Bitcoin, My Nvidia Plan

Cryptos and cash are both headed for a real fight. For their own existence.

Here's How I'm Going to Fix My Position in Merck

Here's How I'm Going to Fix My Position in Merck

This is my fifth worst performing position in a book that contains 62 open positions.

Turn of the Worm, Treasury Curve, Manchin's Might, Trading Microsoft, Spotify

Turn of the Worm, Treasury Curve, Manchin's Might, Trading Microsoft, Spotify

There is a point where if longer-dated yields move high enough, defensive-minded investors will be drawn from equities to debt securities.

Whoa Baby! Here's How I'm Trading Johnson & Johnson After Earnings

Whoa Baby! Here's How I'm Trading Johnson & Johnson After Earnings

The revenue and earnings beats are nice but that's not what really got me fired up.

Silent Tears, My D.C. Solution, Dogs (and Leaders) of the Dow, 2021 Predictions

Silent Tears, My D.C. Solution, Dogs (and Leaders) of the Dow, 2021 Predictions

In 2021, let's support each other as we fight our way out of this mess. Let's learn how to love, and forget how to hate.

Assessing AstraZeneca in the Fight Against the Virus

Assessing AstraZeneca in the Fight Against the Virus

While there are certainly some things to like about AZN, I don't think this vaccine, nor the UK emergency authorization, make it investable.

How I'm Playing Astra-Zeneca on Vaccine and Acquisition News

How I'm Playing Astra-Zeneca on Vaccine and Acquisition News

I am staying away from this name for now, despite the Alexion acquisition and vaccine promise.

November to Remember, Energy Roars, Janet Yellen, Transition, 8 Breakout Stocks

November to Remember, Energy Roars, Janet Yellen, Transition, 8 Breakout Stocks

Equity markets have run wild since Oct. 30, and it is the more economically sensitive indices that have really taken flight.

Jim Cramer: This Is All Playing Out Like a Stephen King Novel

Jim Cramer: This Is All Playing Out Like a Stephen King Novel

What happens when everyone hunkers down, creating their own de facto stay-in-place lockdown?

Jim Cramer: Health Care Stocks, the Election and the Perfect Setup

Jim Cramer: Health Care Stocks, the Election and the Perfect Setup

Right now, the market is furiously trying to price in a Blue Wave, and the health care sector is getting clobbered. But here's how I think things play out.

Red Monday, Virus Rattles Market, Political Picture, Aerospace & Defense Stocks

Red Monday, Virus Rattles Market, Political Picture, Aerospace & Defense Stocks

This is a major earnings week, electoral risk is real, the virus is already slowing velocity, and the cavalry (fiscal policy) is not coming. Sometimes, circling the wagons is not the worst idea.

Pfizer Is Trading a Lot on Hopes Ahead of Earnings

Pfizer Is Trading a Lot on Hopes Ahead of Earnings

Investors are not positioned for an upside move.

Does 'Aggressive' Bristol-Myers Have the Right Prescription for Investors?

Does 'Aggressive' Bristol-Myers Have the Right Prescription for Investors?

BMY's announced acquisition of MyoKardia for $13B comes less than a year after its purchase of Celgene.

With Q3 Earnings Up Ahead, Can Johnson & Johnson Set the Table?

With Q3 Earnings Up Ahead, Can Johnson & Johnson Set the Table?

I see no reason to flee this name, therefore, I am not.

Veeva and RedHill: 2 Stocks to Consider as They Team Up to Battle Covid-19

Veeva and RedHill: 2 Stocks to Consider as They Team Up to Battle Covid-19

RedHill Biopharma has adopted 'Veeva Vault CDMS', Veeva's modern cloud platform.

Parsing the Breakdown of FAANG

Parsing the Breakdown of FAANG

The recent market leaders appear to be running out of steam, while stalwart stocks are grinding higher, with Verizon notable among them.

Biotech M&A Picks Up: Lessons for Investors and Potential Targets

Biotech M&A Picks Up: Lessons for Investors and Potential Targets

The euphoria in biotech stocks Monday was a nice change of pace. It also brought to the forefront some lessons about M&A in this industry.

Is It Safe Now? Wall Street Bets on Science, Joy in Metville, Citi's Selloff

Is It Safe Now? Wall Street Bets on Science, Joy in Metville, Citi's Selloff

Electoral risk remains the monster under the bed, and it only grows as our legislators intentionally choose the blame game over honest cooperation.

Jim Cramer: Is This Market Undervalued?

Jim Cramer: Is This Market Undervalued?

Stocks are reasonable. Or even cheap. There will be more sell-offs ahead but remember this day and do not get too negative.

How About That Merck and Seattle Genetics Deal?

How About That Merck and Seattle Genetics Deal?

I am long Merck, not Seattle Genetics, though the one to own now is obviously SGEN.

Spate of Deal News Juices Start of This Week's Trading

Spate of Deal News Juices Start of This Week's Trading

We've become accustomed lately to gap-up opens on Mondays, but some fresh acquisition agreements are helping drive this Monday's action.

This Biotech Appears to Have the Right Formula for Investors

This Biotech Appears to Have the Right Formula for Investors

After reviewing the rally, let's zero in on one biotech name, Genprex, and where it appears to be going.

The Unusual Suspects: Merck, Coca-Cola and 3M

The Unusual Suspects: Merck, Coca-Cola and 3M

Here are three names among the Dow 30 that are setting up nicely.

Jim Cramer: All These Stocks Are Not Quite 'Dow and Out'

Jim Cramer: All These Stocks Are Not Quite 'Dow and Out'

Let's look at the Dow Jones' swapping of Exxon for Salesforce, Pfizer for Amgen and Raytheon for Honeywell.

Jim Cramer: Betting Against Science Is a Mug's Game

Jim Cramer: Betting Against Science Is a Mug's Game

The buyers have decided that the researchers and doctors are going to beat the virus, so you better get on board or miss the move.